Patient Derived Xenograft (PDX) Models Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Patient Derived Xenograft (PDX) Models Market By 2030 Starting From Its 2026 Size?
The patient derived xenograft (pdx) models market has seen substantial growth recently. It is projected to expand from $0.47 billion in 2025 to $0.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.8%. Historically, this growth is attributable to factors such as the restricted predictive capacity of traditional cell line models, the increasing number of cancer research initiatives, the reliance on animal models for drug testing, the escalating demand for translational oncology studies, and the broadening of collaborations between academic and pharmaceutical research entities.
The patient derived xenograft (pdx) models market size is projected for substantial expansion in the coming years. This market is anticipated to reach a valuation of $0.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. Key drivers for this growth during the forecast period include the increasing adoption of pdx models in precision medicine, greater investment in humanized mouse and rat models, the expansion of co-clinical trial initiatives, the proliferation of contract research services providing pdx solutions, and the growing application of pdx models for assessing immunotherapies and targeted therapies. Noteworthy trends anticipated in this period encompass the wider use of pdx models for preclinical drug development, an escalating emphasis on personalized cancer research employing pdx models, the increasing incorporation of digital platforms for managing tumor data, a higher reliance on humanized and genetically modified models, and the expanding scope of co-clinical trials that utilize pdx models.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
What Drivers Are Shaping The Future Growth Of The Patient Derived Xenograft (PDX) Models Market?
The future expansion of the patient-derived xenograft (PDX) models market is anticipated to be fueled by the rising need for personalized medicine. Personalized medicine customizes medical care for individual patients, taking into account their unique genetic makeup, environmental influences, and lifestyle choices. This demand is escalating, driven by progress in genomic research that facilitates customized treatments aligning with individual genetic profiles, thereby achieving more precise and impactful healthcare results. Patient-derived xenograft (PDX) models support personalized medicine by enabling the testing of tumors from individual patients to forecast how they might respond to treatment and to adjust therapies appropriately. For example, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, showed in February 2024 that the FDA cleared 16 new personalized therapies for rare diseases in 2023, which represents a substantial rise from the six approvals seen in 2022. Consequently, the growing requirement for personalized medicine is a key impetus behind the expansion of the patient-derived xenograft (PDX) models market.
Which Segment Categories Define The Patient Derived Xenograft (PDX) Models Market?
The patient derived xenograft (pdx) models market covered in this report is segmented –
1) By Type: Mice Models, Rat Models
2) By Technique: Heterotopic Implantation, Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models
4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research
5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models
Which Upcoming Trends Are Expected To Influence The Patient Derived Xenograft (PDX) Models Market?
Major firms within the patient-derived xenograft (PDX) models market are crafting advanced models that incorporate in vivo bioluminescence imaging functions, facilitating the continuous observation of tumor development. This bioluminescence imaging capability assists PDX models by providing non-invasive, real-time tracking of tumor spread and reactions to treatment, thereby boosting the efficiency of preclinical investigations in pharmaceutical development. For example, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), introduced a pioneering orthotopic model for human glioblastoma in NSG-SGM3 mice, utilizing both patient-derived xenografts (PDX) and in vivo bioluminescence imaging. The objective of this model is to enable tailored treatment approaches for glioblastoma, which stands as the most prevalent and aggressive form of brain cancer. Such models are vital for comprehending glioblastoma’s biological mechanisms and for assessing novel targeted and immunotherapeutic treatments to enhance patient results.
Who Are The Top Companies Competing In The Patient Derived Xenograft (PDX) Models Market?
Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.
Read the full patient derived xenograft (pdx) models market report here:
Which Geographic Regions Are Influencing Demand In The Patient Derived Xenograft (PDX) Models Market?
North America was the largest region in the patient derived xenograft (PDX) models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (pdx) models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Patient Derived Xenograft (PDX) Models Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp
Browse Through More Reports Similar to the Global Patient Derived Xenograft (PDX) Models Market 2026, By The Business Research Company
Healthcare Data Interoperability Global Market Report
Patient Registry Software Global Market Report
https://www.thebusinessresearchcompany.com/report/patient-registry-software-global-market-report
Clinical Data Analytics Solutions Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
